{"id":17729,"date":"2023-12-05T01:31:16","date_gmt":"2023-12-05T01:31:16","guid":{"rendered":"https:\/\/www.canaaf.org\/?p=17729"},"modified":"2024-02-15T22:26:18","modified_gmt":"2024-02-15T22:26:18","slug":"homologation-de-sante-canada-litfulomc-devient-le-premier-traitement-autorise-de-lalopecie-areata-severe-au-canada","status":"publish","type":"post","link":"https:\/\/www.canaaf.org\/fr\/homologation-de-sante-canada-litfulomc-devient-le-premier-traitement-autorise-de-lalopecie-areata-severe-au-canada\/","title":{"rendered":"Homologation de Sant\u00e9 Canada : LITFULOMC devient le premier traitement autoris\u00e9 de l\u2019alop\u00e9cie areata s\u00e9v\u00e8re au Canada"},"content":{"rendered":"<p>Ce communiqu\u00e9 a \u00e9t\u00e9 mis en ligne le 4 d\u00e9cembre 2023 sur <a href=\"https:\/\/www.pfizer.ca\/fr\/centre-de-presse\/homologation-de-sant%C3%A9-canada-litfulomc-devient-le-premier-traitement-autoris%C3%A9-de-lalop%C3%A9cie-areata-s%C3%A9v%C3%A8re-au-canada\/\">le site de Pfizer<\/a>.<\/p>\n<p><em>LITFULO<sup>MC<\/sup>\u00a0(ritl\u00e9citinib), un inhibiteur de JAK3 et des kinases de la famille\u00a0Tec, est homologu\u00e9 pour le traitement de l\u2019alop\u00e9cie areata s\u00e9v\u00e8re des adultes et des adolescents de 12\u00a0ans et plus.<\/em><\/p>\n<p>KIRKLAND (Qu\u00e9bec), 4 d\u00e9cembre\u00a02023 \u2013 Pfizer Canada a annonc\u00e9 aujourd\u2019hui que Sant\u00e9 Canada a accord\u00e9 un avis de conformit\u00e9 (AC) \u00e0 LITFULO<sup>MC<\/sup>\u00a0(ritl\u00e9citinib). LITFULO, une capsule \u00e0 prise orale uniquotidienne, est le premier et le seul produit homologu\u00e9 par Sant\u00e9 Canada pour le traitement de l\u2019alop\u00e9cie areata s\u00e9v\u00e8re des personnes de 12\u00a0ans et plus<sup>[i]<\/sup>. L\u2019alop\u00e9cie areata touche environ deux pour cent de la population mondiale; il s\u2019agit d\u2019une maladie auto-immune dans laquelle le syst\u00e8me immunitaire s\u2019attaque aux follicules pileux, ce qui entra\u00eene une perte totale ou par plaques des cheveux et des poils sur le cuir chevelu, le visage ou le corps<sup>[ii],[iii],[iv]<\/sup>.<\/p>\n<p>\u00ab\u00a0L\u2019alop\u00e9cie areata est une maladie auto-immune qui peut \u00eatre difficile \u00e0 g\u00e9rer physiquement et \u00e9motionnellement pour les patients, particuli\u00e8rement pour les jeunes, a d\u00e9clar\u00e9 la D<sup>re<\/sup>\u00a0Catherine Maari, dermatologue et professeure agr\u00e9g\u00e9e de m\u00e9decine, Universit\u00e9 de Montr\u00e9al. Gr\u00e2ce \u00e0 l\u2019approbation de LITFULO par Sant\u00e9 Canada, les dermatologues comme moi disposent d\u00e9sormais d\u2019un nouveau traitement approuv\u00e9 pour aider les patients aux prises avec cette maladie difficile.\u00a0\u00bb<\/p>\n<p>On estime que 775\u00a0000\u00a0Canadiens seront touch\u00e9s par l\u2019alop\u00e9cie areata \u00e0 un moment donn\u00e9 de leur vie; dans la plupart des cas, les premiers signes apparaissent entre l\u2019adolescence et la trentaine. Toutefois, les sympt\u00f4mes peuvent se manifester \u00e0 tout \u00e2ge, et pr\u00e8s de 20 pour cent des patients re\u00e7oivent un diagnostic avant l\u2019\u00e2ge de 18\u00a0ans<sup>[v],[vi],[vii]<\/sup>.<\/p>\n<p>\u00ab\u00a0L\u2019alop\u00e9cie areata peut avoir des cons\u00e9quences n\u00e9fastes majeures sur la sant\u00e9 mentale et la qualit\u00e9 de vie, a indiqu\u00e9 Carolynne Harrison, pr\u00e9sidente de la\u00a0Fondation canadienne de l\u2019alop\u00e9cie areata (FCANAA). Jusqu\u2019\u00e0 aujourd\u2019hui, nous ne pouvions compter sur aucun traitement m\u00e9dical homologu\u00e9 pour aider les patients et leurs familles. Les personnes touch\u00e9es par l\u2019alop\u00e9cie au Canada sont toutes impatientes d\u2019avoir acc\u00e8s \u00e0 un nouveau traitement destin\u00e9 \u00e0 la fois aux adolescents et aux adultes atteints d\u2019une forme s\u00e9v\u00e8re de la maladie.\u00a0\u00bb<\/p>\n<p><strong>Au sujet de l\u2019alop\u00e9cie areata<\/strong><br \/>\nL\u2019alop\u00e9cie areata est une maladie auto-immune \u00e0 m\u00e9diation cellulaire (lymphocytes\u00a0T) qui s\u2019attaque aux follicules pileux. L\u2019inflammation des follicules entra\u00eene la perte des cheveux et emp\u00eache leur repousse tant que la r\u00e9ponse immunitaire n\u2019est pas supprim\u00e9e<sup>[viii]<\/sup>. Cette perte touche souvent le cuir chevelu, mais elle peut aussi concerner les sourcils, les cils, les poils du visage ou d\u2019autres r\u00e9gions du corps<sup>[ix],[x]<\/sup>. L\u2019alop\u00e9cie areata peut toucher des personnes de tout \u00e2ge, de tout sexe, de toute race ou de toute origine ethnique; au-del\u00e0 de la perte de cheveux, elle repr\u00e9sente un fardeau consid\u00e9rable<sup>[xi],[xii],[xiii],[xiv]<\/sup>.<\/p>\n<p>\u00ab\u00a0L\u2019homologation de LITFULO repr\u00e9sente un jalon important pour les Canadiens, dont certains \u00e2g\u00e9s d\u2019\u00e0 peine 12\u00a0ans, qui sont touch\u00e9s par une perte de cheveux s\u00e9v\u00e8re caus\u00e9e par l\u2019alop\u00e9cie areata, a d\u00e9clar\u00e9 Fr\u00e9d\u00e9ric Lavoie, leader \u2013 Inflammation et immunologie de Pfizer Canada. Cette d\u00e9cision marque l\u2019arriv\u00e9e du premier produit homologu\u00e9 par Sant\u00e9 Canada pour le traitement de l\u2019alop\u00e9cie areata s\u00e9v\u00e8re. En tant que chef de file en inflammation et immunologie, Pfizer Canada est particuli\u00e8rement fi\u00e8re d\u2019offrir cette nouvelle option aux Canadiens aux prises avec cette maladie auto-immune difficile \u00e0 traiter.\u00a0\u00bb<\/p>\n<p>Pfizer Canada \u00e9value actuellement la date \u00e0 laquelle LITFULO deviendra disponible au Canada et s\u2019engage \u00e0 offrir le produit aux Canadiens le plus rapidement possible.<\/p>\n<p><strong>Au sujet de LITFULO<sup>MC<\/sup><\/strong><br \/>\nLITFULO est employ\u00e9 pour le traitement de l\u2019alop\u00e9cie areata s\u00e9v\u00e8re des personnes de 12\u00a0ans et plus<sup>[xv]<\/sup>. LITFULO est un inhibiteur de JAK3 et des kinases de la famille Tec<sup>[xvi]<\/sup>. L\u2019inhibition de JAK3 et des kinases de la famille Tec par LITFULO pourrait bloquer la signalisation par des cytokines et l\u2019activit\u00e9 cytolytique des lymphocytes\u00a0T, qui interviennent dans la pathogen\u00e8se de l\u2019alop\u00e9cie areata<sup>[xvii]<\/sup>.<\/p>\n<p><strong>\u00c0 propos de Pfizer Canada<\/strong><br \/>\nPfizer Canada SRI est la filiale canadienne de Pfizer Inc., l\u2019une des principales entreprises biopharmaceutiques \u00e0 l\u2019\u00e9chelle mondiale. Notre gamme diversifi\u00e9e de produits de soins de sant\u00e9 comprend des m\u00e9dicaments et des vaccins figurant parmi les plus populaires et les plus prescrits dans le monde. Nous mettons \u00e0 profit la science et nos ressources mondiales pour am\u00e9liorer la sant\u00e9 et le bien-\u00eatre de la population canadienne, \u00e0 toutes les \u00e9tapes de la vie. Notre engagement se refl\u00e8te dans tout ce que nous faisons \u2013 qu\u2019il s\u2019agisse d\u2019initiatives de sensibilisation aux maladies ou de partenariats communautaires. Pour en savoir plus sur Pfizer Canada, visitez\u00a0<a href=\"https:\/\/www.pfizer.ca\/\">pfizer.ca\/fr\/\u00a0<\/a>ou suivez-nous sur\u00a0<a href=\"https:\/\/www.linkedin.com\/company\/pfizer\">LinkedIn<\/a>,\u00a0<a href=\"https:\/\/www.facebook.com\/Pfizer.Canada\/\">Facebook<\/a>,\u00a0<a href=\"https:\/\/twitter.com\/PfizerCA\">X<\/a>\u00a0ou\u00a0<a href=\"https:\/\/www.youtube.com\/channel\/UCHYITGP-kzfpkbvHz6BTjEQ\/featured\">YouTube<\/a>.<\/p>\n<p><strong>Pour de plus amples renseignements\u00a0:<\/strong><br \/>\nAffaires de l\u2019entreprise \u2013 Canada<br \/>\n1-866-9Pfizer (1-866-973-4937)<br \/>\ncorporate.affairs.canada@pfizer.com<\/p>\n<p>[i] Monographie de LITFULO. Accessible au www.pfizer.ca. 29 novembre 2023.<\/p>\n<p>[ii] Fondation canadienne de l\u2019alop\u00e9cie areata. Qu\u2019est-ce que l\u2019alop\u00e9cie areata? Consult\u00e9 en novembre\u00a02023 \u00e0 l\u2019adresse https:\/\/www.canaaf.org\/fr\/a-propos-de-lalopecie-areata\/.<\/p>\n<p>[iii] Association canadienne de dermatologie. L\u2019alop\u00e9cie. Consult\u00e9 en novembre\u00a02023 \u00e0 l\u2019adresse https:\/\/dermatologue.ca\/patients-et-grand-public\/cheveux\/alopecie\/.<\/p>\n<p>[iv] Islam N, Leung PSC, Huntley AC, et al. The autoimmune basis of alopecia areata: a comprehensive review. Autoimmun Rev. 2015:14(2):81-89.<\/p>\n<p>[v] National Institute of Arthritis and Musculoskeletal and Skin Diseases. Alopecia Areata. Consult\u00e9 en novembre\u00a02023 \u00e0 l\u2019adresse https:\/\/www.niams.nih.gov\/health-topics\/alopecia-areata.<\/p>\n<p>[vi] Caldwell CC, Saikaly SK, Dellavalle RP, et al. Prevalence of pediatric alopecia areata among 572,617 dermatology patients.<br \/>\nJ Am Acad of Dermatol. 2017;77(5):980-981.<\/p>\n<p>[vii] Gilding AJ, Ho N, Pope E, Sibbald C. The Burden of Disease in Alopecia Areata: Canadian Online Survey of Patients and Caregivers. JMIR Dermatol. 6\u00a0oct.\u00a02022 6;5(4):e39167<\/p>\n<p>[viii] Fondation canadienne de l\u2019alop\u00e9cie areata. Qu\u2019est-ce que l\u2019alop\u00e9cie areata? Consult\u00e9 en novembre\u00a02023 \u00e0 l\u2019adresse https:\/\/www.canaaf.org\/fr\/a-propos-de-lalopecie-areata\/.<\/p>\n<p>[ix] Association canadienne de dermatologie. L\u2019alop\u00e9cie. Consult\u00e9 le 13\u00a0novembre\u00a02023 \u00e0 l\u2019adresse https:\/\/dermatologue.ca\/patients-et-grand-public\/cheveux\/alopecie\/.<\/p>\n<p>[x] Islam N, Leung PSC, Huntley AC, et al. The autoimmune basis of alopecia areata: a comprehensive review. Autoimmun Rev. 2015:14(2):81-89.<\/p>\n<p>[xi] Association canadienne de dermatologie. L\u2019alop\u00e9cie. Consult\u00e9 le 13\u00a0novembre\u00a02023 \u00e0 l\u2019adresse https:\/\/dermatologue.ca\/patients-et-grand-public\/cheveux\/alopecie\/.<\/p>\n<p>[xii] Islam N, Leung PSC, Huntley AC, et al. The autoimmune basis of alopecia areata: a comprehensive review. Autoimmun Rev. 2015:14(2):81-89.<\/p>\n<p>[xiii] Food and Drug Administration. The voice of the patient: a series of reports from the U.S. Food and Drug Administration\u2019s (FDA\u2019s) patient-focused drug development initiative. Silver Spring, MD:FDA;2018. Accessible au\u00a0https:\/\/www.fda.gov\/files\/about%20fda\/published\/Alopecia-Areata&#8211;The-Voice-of-the-Patient.pdf. Consult\u00e9 le 11\u00a0novembre\u00a02023.<\/p>\n<p>[xiv] Stefanaki C, Kontochristopoulos G, Hatzidimitrakib E, et al. A Retrospective Study on Alopecia Areata in Children: Clinical Characteristics and Treatment Choices. Skin Appen Dis. 2021.<\/p>\n<p>[xv] Monographie de LITFULO. Accessible au www.pfizer.ca. 29 novembre 2023.<\/p>\n<p>[xvi] Ibid.<\/p>\n<p>[xvii] Ibid.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ce communiqu\u00e9 a \u00e9t\u00e9 mis en ligne le 4 d\u00e9cembre 2023 sur le site de Pfizer. LITFULOMC\u00a0(ritl\u00e9citinib), un inhibiteur de JAK3 et [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":15462,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[342],"tags":[],"class_list":["post-17729","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-non-classifiee"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Homologation de Sant\u00e9 Canada : LITFULOMC devient le premier traitement autoris\u00e9 de l\u2019alop\u00e9cie areata s\u00e9v\u00e8re au Canada - Fondation Canadienne de l\u2019Alop\u00e9cie Areata<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.canaaf.org\/fr\/homologation-de-sante-canada-litfulomc-devient-le-premier-traitement-autorise-de-lalopecie-areata-severe-au-canada\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Homologation de Sant\u00e9 Canada : LITFULOMC devient le premier traitement autoris\u00e9 de l\u2019alop\u00e9cie areata s\u00e9v\u00e8re au Canada - Fondation Canadienne de l\u2019Alop\u00e9cie Areata\" \/>\n<meta property=\"og:description\" content=\"Ce communiqu\u00e9 a \u00e9t\u00e9 mis en ligne le 4 d\u00e9cembre 2023 sur le site de Pfizer. LITFULOMC\u00a0(ritl\u00e9citinib), un inhibiteur de JAK3 et [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.canaaf.org\/fr\/homologation-de-sante-canada-litfulomc-devient-le-premier-traitement-autorise-de-lalopecie-areata-severe-au-canada\/\" \/>\n<meta property=\"og:site_name\" content=\"Fondation Canadienne de l\u2019Alop\u00e9cie Areata\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-05T01:31:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-02-15T22:26:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.canaaf.org\/wp-content\/uploads\/2021\/09\/Pfizer_Logo_Color_RGB.png\" \/>\n\t<meta property=\"og:image:width\" content=\"2048\" \/>\n\t<meta property=\"og:image:height\" content=\"845\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"canaaf\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"canaaf\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.canaaf.org\\\/fr\\\/homologation-de-sante-canada-litfulomc-devient-le-premier-traitement-autorise-de-lalopecie-areata-severe-au-canada\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.canaaf.org\\\/fr\\\/homologation-de-sante-canada-litfulomc-devient-le-premier-traitement-autorise-de-lalopecie-areata-severe-au-canada\\\/\"},\"author\":{\"name\":\"canaaf\",\"@id\":\"https:\\\/\\\/www.canaaf.org\\\/fr\\\/#\\\/schema\\\/person\\\/a056c978f094cc8f7b758a61444d18a1\"},\"headline\":\"Homologation de Sant\u00e9 Canada : LITFULOMC devient le premier traitement autoris\u00e9 de l\u2019alop\u00e9cie areata s\u00e9v\u00e8re au Canada\",\"datePublished\":\"2023-12-05T01:31:16+00:00\",\"dateModified\":\"2024-02-15T22:26:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.canaaf.org\\\/fr\\\/homologation-de-sante-canada-litfulomc-devient-le-premier-traitement-autorise-de-lalopecie-areata-severe-au-canada\\\/\"},\"wordCount\":1241,\"image\":{\"@id\":\"https:\\\/\\\/www.canaaf.org\\\/fr\\\/homologation-de-sante-canada-litfulomc-devient-le-premier-traitement-autorise-de-lalopecie-areata-severe-au-canada\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.canaaf.org\\\/wp-content\\\/uploads\\\/2021\\\/09\\\/Pfizer_Logo_Color_RGB.png\",\"articleSection\":[\"Non classifi\u00e9(e)\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.canaaf.org\\\/fr\\\/homologation-de-sante-canada-litfulomc-devient-le-premier-traitement-autorise-de-lalopecie-areata-severe-au-canada\\\/\",\"url\":\"https:\\\/\\\/www.canaaf.org\\\/fr\\\/homologation-de-sante-canada-litfulomc-devient-le-premier-traitement-autorise-de-lalopecie-areata-severe-au-canada\\\/\",\"name\":\"Homologation de Sant\u00e9 Canada : LITFULOMC devient le premier traitement autoris\u00e9 de l\u2019alop\u00e9cie areata s\u00e9v\u00e8re au Canada - Fondation Canadienne de l\u2019Alop\u00e9cie Areata\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.canaaf.org\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.canaaf.org\\\/fr\\\/homologation-de-sante-canada-litfulomc-devient-le-premier-traitement-autorise-de-lalopecie-areata-severe-au-canada\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.canaaf.org\\\/fr\\\/homologation-de-sante-canada-litfulomc-devient-le-premier-traitement-autorise-de-lalopecie-areata-severe-au-canada\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.canaaf.org\\\/wp-content\\\/uploads\\\/2021\\\/09\\\/Pfizer_Logo_Color_RGB.png\",\"datePublished\":\"2023-12-05T01:31:16+00:00\",\"dateModified\":\"2024-02-15T22:26:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.canaaf.org\\\/fr\\\/#\\\/schema\\\/person\\\/a056c978f094cc8f7b758a61444d18a1\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.canaaf.org\\\/fr\\\/homologation-de-sante-canada-litfulomc-devient-le-premier-traitement-autorise-de-lalopecie-areata-severe-au-canada\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.canaaf.org\\\/fr\\\/homologation-de-sante-canada-litfulomc-devient-le-premier-traitement-autorise-de-lalopecie-areata-severe-au-canada\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.canaaf.org\\\/fr\\\/homologation-de-sante-canada-litfulomc-devient-le-premier-traitement-autorise-de-lalopecie-areata-severe-au-canada\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.canaaf.org\\\/wp-content\\\/uploads\\\/2021\\\/09\\\/Pfizer_Logo_Color_RGB.png\",\"contentUrl\":\"https:\\\/\\\/www.canaaf.org\\\/wp-content\\\/uploads\\\/2021\\\/09\\\/Pfizer_Logo_Color_RGB.png\",\"width\":2048,\"height\":845},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.canaaf.org\\\/fr\\\/homologation-de-sante-canada-litfulomc-devient-le-premier-traitement-autorise-de-lalopecie-areata-severe-au-canada\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.canaaf.org\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Homologation de Sant\u00e9 Canada : LITFULOMC devient le premier traitement autoris\u00e9 de l\u2019alop\u00e9cie areata s\u00e9v\u00e8re au Canada\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.canaaf.org\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.canaaf.org\\\/fr\\\/\",\"name\":\"Fondation Canadienne de l\u2019Alop\u00e9cie Areata\",\"description\":\"Pr\u00e9visible pour une maladie impr\u00e9visible.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.canaaf.org\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.canaaf.org\\\/fr\\\/#\\\/schema\\\/person\\\/a056c978f094cc8f7b758a61444d18a1\",\"name\":\"canaaf\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9e9992e9fe9731aca2131364fdeebff31804bf3f824bf344845475871356a949?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9e9992e9fe9731aca2131364fdeebff31804bf3f824bf344845475871356a949?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9e9992e9fe9731aca2131364fdeebff31804bf3f824bf344845475871356a949?s=96&d=mm&r=g\",\"caption\":\"canaaf\"},\"url\":\"https:\\\/\\\/www.canaaf.org\\\/fr\\\/author\\\/canaaf\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Homologation de Sant\u00e9 Canada : LITFULOMC devient le premier traitement autoris\u00e9 de l\u2019alop\u00e9cie areata s\u00e9v\u00e8re au Canada - Fondation Canadienne de l\u2019Alop\u00e9cie Areata","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.canaaf.org\/fr\/homologation-de-sante-canada-litfulomc-devient-le-premier-traitement-autorise-de-lalopecie-areata-severe-au-canada\/","og_locale":"fr_FR","og_type":"article","og_title":"Homologation de Sant\u00e9 Canada : LITFULOMC devient le premier traitement autoris\u00e9 de l\u2019alop\u00e9cie areata s\u00e9v\u00e8re au Canada - Fondation Canadienne de l\u2019Alop\u00e9cie Areata","og_description":"Ce communiqu\u00e9 a \u00e9t\u00e9 mis en ligne le 4 d\u00e9cembre 2023 sur le site de Pfizer. LITFULOMC\u00a0(ritl\u00e9citinib), un inhibiteur de JAK3 et [&hellip;]","og_url":"https:\/\/www.canaaf.org\/fr\/homologation-de-sante-canada-litfulomc-devient-le-premier-traitement-autorise-de-lalopecie-areata-severe-au-canada\/","og_site_name":"Fondation Canadienne de l\u2019Alop\u00e9cie Areata","article_published_time":"2023-12-05T01:31:16+00:00","article_modified_time":"2024-02-15T22:26:18+00:00","og_image":[{"width":2048,"height":845,"url":"https:\/\/www.canaaf.org\/wp-content\/uploads\/2021\/09\/Pfizer_Logo_Color_RGB.png","type":"image\/png"}],"author":"canaaf","twitter_misc":{"\u00c9crit par":"canaaf","Dur\u00e9e de lecture estim\u00e9e":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.canaaf.org\/fr\/homologation-de-sante-canada-litfulomc-devient-le-premier-traitement-autorise-de-lalopecie-areata-severe-au-canada\/#article","isPartOf":{"@id":"https:\/\/www.canaaf.org\/fr\/homologation-de-sante-canada-litfulomc-devient-le-premier-traitement-autorise-de-lalopecie-areata-severe-au-canada\/"},"author":{"name":"canaaf","@id":"https:\/\/www.canaaf.org\/fr\/#\/schema\/person\/a056c978f094cc8f7b758a61444d18a1"},"headline":"Homologation de Sant\u00e9 Canada : LITFULOMC devient le premier traitement autoris\u00e9 de l\u2019alop\u00e9cie areata s\u00e9v\u00e8re au Canada","datePublished":"2023-12-05T01:31:16+00:00","dateModified":"2024-02-15T22:26:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.canaaf.org\/fr\/homologation-de-sante-canada-litfulomc-devient-le-premier-traitement-autorise-de-lalopecie-areata-severe-au-canada\/"},"wordCount":1241,"image":{"@id":"https:\/\/www.canaaf.org\/fr\/homologation-de-sante-canada-litfulomc-devient-le-premier-traitement-autorise-de-lalopecie-areata-severe-au-canada\/#primaryimage"},"thumbnailUrl":"https:\/\/www.canaaf.org\/wp-content\/uploads\/2021\/09\/Pfizer_Logo_Color_RGB.png","articleSection":["Non classifi\u00e9(e)"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.canaaf.org\/fr\/homologation-de-sante-canada-litfulomc-devient-le-premier-traitement-autorise-de-lalopecie-areata-severe-au-canada\/","url":"https:\/\/www.canaaf.org\/fr\/homologation-de-sante-canada-litfulomc-devient-le-premier-traitement-autorise-de-lalopecie-areata-severe-au-canada\/","name":"Homologation de Sant\u00e9 Canada : LITFULOMC devient le premier traitement autoris\u00e9 de l\u2019alop\u00e9cie areata s\u00e9v\u00e8re au Canada - Fondation Canadienne de l\u2019Alop\u00e9cie Areata","isPartOf":{"@id":"https:\/\/www.canaaf.org\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.canaaf.org\/fr\/homologation-de-sante-canada-litfulomc-devient-le-premier-traitement-autorise-de-lalopecie-areata-severe-au-canada\/#primaryimage"},"image":{"@id":"https:\/\/www.canaaf.org\/fr\/homologation-de-sante-canada-litfulomc-devient-le-premier-traitement-autorise-de-lalopecie-areata-severe-au-canada\/#primaryimage"},"thumbnailUrl":"https:\/\/www.canaaf.org\/wp-content\/uploads\/2021\/09\/Pfizer_Logo_Color_RGB.png","datePublished":"2023-12-05T01:31:16+00:00","dateModified":"2024-02-15T22:26:18+00:00","author":{"@id":"https:\/\/www.canaaf.org\/fr\/#\/schema\/person\/a056c978f094cc8f7b758a61444d18a1"},"breadcrumb":{"@id":"https:\/\/www.canaaf.org\/fr\/homologation-de-sante-canada-litfulomc-devient-le-premier-traitement-autorise-de-lalopecie-areata-severe-au-canada\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.canaaf.org\/fr\/homologation-de-sante-canada-litfulomc-devient-le-premier-traitement-autorise-de-lalopecie-areata-severe-au-canada\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.canaaf.org\/fr\/homologation-de-sante-canada-litfulomc-devient-le-premier-traitement-autorise-de-lalopecie-areata-severe-au-canada\/#primaryimage","url":"https:\/\/www.canaaf.org\/wp-content\/uploads\/2021\/09\/Pfizer_Logo_Color_RGB.png","contentUrl":"https:\/\/www.canaaf.org\/wp-content\/uploads\/2021\/09\/Pfizer_Logo_Color_RGB.png","width":2048,"height":845},{"@type":"BreadcrumbList","@id":"https:\/\/www.canaaf.org\/fr\/homologation-de-sante-canada-litfulomc-devient-le-premier-traitement-autorise-de-lalopecie-areata-severe-au-canada\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.canaaf.org\/fr\/"},{"@type":"ListItem","position":2,"name":"Homologation de Sant\u00e9 Canada : LITFULOMC devient le premier traitement autoris\u00e9 de l\u2019alop\u00e9cie areata s\u00e9v\u00e8re au Canada"}]},{"@type":"WebSite","@id":"https:\/\/www.canaaf.org\/fr\/#website","url":"https:\/\/www.canaaf.org\/fr\/","name":"Fondation Canadienne de l\u2019Alop\u00e9cie Areata","description":"Pr\u00e9visible pour une maladie impr\u00e9visible.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.canaaf.org\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.canaaf.org\/fr\/#\/schema\/person\/a056c978f094cc8f7b758a61444d18a1","name":"canaaf","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/9e9992e9fe9731aca2131364fdeebff31804bf3f824bf344845475871356a949?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/9e9992e9fe9731aca2131364fdeebff31804bf3f824bf344845475871356a949?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9e9992e9fe9731aca2131364fdeebff31804bf3f824bf344845475871356a949?s=96&d=mm&r=g","caption":"canaaf"},"url":"https:\/\/www.canaaf.org\/fr\/author\/canaaf\/"}]}},"_links":{"self":[{"href":"https:\/\/www.canaaf.org\/fr\/wp-json\/wp\/v2\/posts\/17729","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.canaaf.org\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.canaaf.org\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.canaaf.org\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.canaaf.org\/fr\/wp-json\/wp\/v2\/comments?post=17729"}],"version-history":[{"count":3,"href":"https:\/\/www.canaaf.org\/fr\/wp-json\/wp\/v2\/posts\/17729\/revisions"}],"predecessor-version":[{"id":17860,"href":"https:\/\/www.canaaf.org\/fr\/wp-json\/wp\/v2\/posts\/17729\/revisions\/17860"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.canaaf.org\/fr\/wp-json\/wp\/v2\/media\/15462"}],"wp:attachment":[{"href":"https:\/\/www.canaaf.org\/fr\/wp-json\/wp\/v2\/media?parent=17729"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.canaaf.org\/fr\/wp-json\/wp\/v2\/categories?post=17729"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.canaaf.org\/fr\/wp-json\/wp\/v2\/tags?post=17729"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}